Article
The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia.
Leukemia - 1 Jan 2015
Cao Y, Hunter Z R, Liu X, Xu L, Yang G, Chen J, Patterson C J, Tsakmaklis N, Kanan S, Rodig S, Castillo J J, Treon S P
Abstract excerpt
CXCR4(WHIM) somatic mutations are common Waldenstrom's Macroglobulinemia (WM), and are associated with clinical resistance to ibrutinib. We engineered WM cells to express the most common WHIM (Warts, Hypogammaglobulinemia, Infections and Myelokathexis), CXCR(S338X) mutation in WM. Following SDF-1...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.